Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNSP NASDAQ:LGVN NASDAQ:PTPI NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$4.17-2.8%$4.50$1.90▼$12.36$6.27M3.0622,257 shs13,597 shsLGVNLongeveron$0.74-7.5%$0.84$0.48▼$1.80$24.92M-0.35202,593 shs256,602 shsPTPIPetros Pharmaceuticals$0.01+3.4%$0.01$0.00▼$0.04$187K1.87103,267 shs35,560 shsSKYESkye Bioscience$0.68-3.0%$0.80$0.57▼$5.75$24.60M2.95183,247 shs84,882 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals+0.23%-7.34%-20.85%+57.14%-52.90%LGVNLongeveron-0.05%+3.90%-2.46%-17.79%-30.43%PTPIPetros Pharmaceuticals-1.69%-3.33%-4.92%-17.14%-80.73%SKYESkye Bioscience-1.24%-2.56%-15.59%+12.04%-75.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$4.17-2.8%$4.50$1.90▼$12.36$6.27M3.0622,257 shs13,597 shsLGVNLongeveron$0.74-7.5%$0.84$0.48▼$1.80$24.92M-0.35202,593 shs256,602 shsPTPIPetros Pharmaceuticals$0.01+3.4%$0.01$0.00▼$0.04$187K1.87103,267 shs35,560 shsSKYESkye Bioscience$0.68-3.0%$0.80$0.57▼$5.75$24.60M2.95183,247 shs84,882 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals+0.23%-7.34%-20.85%+57.14%-52.90%LGVNLongeveron-0.05%+3.90%-2.46%-17.79%-30.43%PTPIPetros Pharmaceuticals-1.69%-3.33%-4.92%-17.14%-80.73%SKYESkye Bioscience-1.24%-2.56%-15.59%+12.04%-75.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSPCNS Pharmaceuticals 2.00Hold$20.00377.33% UpsideLGVNLongeveron 2.25Hold$5.50624.64% UpsidePTPIPetros Pharmaceuticals 0.00N/AN/AN/ASKYESkye Bioscience 2.50Moderate Buy$8.501,172.46% UpsideCurrent Analyst Ratings BreakdownLatest CNSP, PTPI, LGVN, and SKYE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LGVNLongeveron Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/4/2026LGVNLongeveron HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.004/21/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CNSPCNS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSPCNS PharmaceuticalsN/AN/AN/AN/A$7.29 per shareN/ALGVNLongeveron$1.22M19.44N/AN/A$0.25 per share3.04PTPIPetros Pharmaceuticals$5.11M0.04N/AN/A$4.04 per share0.00SKYESkye BioscienceN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSPCNS Pharmaceuticals-$15.85M-$29.63N/AN/AN/AN/A-238.68%-166.30%8/17/2026 (Estimated)LGVNLongeveron-$22.70M-$1.13N/AN/AN/A-1,844.49%-202.41%-140.67%8/12/2026 (Estimated)PTPIPetros Pharmaceuticals-$8.16M-$1.64N/AN/AN/AN/A-78.22%-23.50%N/ASKYESkye Bioscience-$55.92M-$1.44N/AN/AN/AN/A-217.27%-162.39%N/ALatest CNSP, PTPI, LGVN, and SKYE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CNSPCNS Pharmaceuticals-$8.82-$7.30+$1.52-$7.30N/AN/A5/13/2026Q1 2026LGVNLongeveron-$0.19-$0.19N/A-$0.19$0.33 million$0.40 million5/11/2026Q1 2026SKYESkye Bioscience-$0.29-$0.32-$0.03-$0.32N/AN/A3/31/2026Q4 2025CNSPCNS Pharmaceuticals-$5.37-$10.15-$4.78-$10.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSPCNS PharmaceuticalsN/A0.890.89LGVNLongeveron0.053.883.88PTPIPetros Pharmaceuticals1.580.850.74SKYESkye BioscienceN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSPCNS Pharmaceuticals14.02%LGVNLongeveron10.01%PTPIPetros Pharmaceuticals12.34%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipCNSPCNS Pharmaceuticals0.01%LGVNLongeveron7.42%PTPIPetros Pharmaceuticals8.23%SKYESkye Bioscience6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSPCNS Pharmaceuticals51.46 million1.46 millionNot OptionableLGVNLongeveron2031.15 million28.84 millionNot OptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableSKYESkye Bioscience1135.14 million32.97 millionOptionableCNSP, PTPI, LGVN, and SKYE HeadlinesRecent News About These CompaniesSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Moderate Buy" from BrokeragesJune 18, 2026 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Stock Price Down 7.3% - Should You Sell?June 16, 2026 | americanbankingnews.comSkye Bioscience Expands Authorized Shares After Shareholder ApprovalMay 29, 2026 | tipranks.comSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1May 20, 2026 | globenewswire.comSkye Bioscience (SKYE) price target decreased by 11.48% to 7.87May 14, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)May 14, 2026 | theglobeandmail.comSkye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | finanznachrichten.dePomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYEMay 13, 2026 | natlawreview.comNSkye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026May 12, 2026 | quiverquant.comQUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 12, 2026 | globenewswire.comSkye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 11, 2026 | globenewswire.comKuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law FirmApril 22, 2026 | globenewswire.comSkye Bioscience Presenting at GLP-1-Based Therapeutics SummitApril 7, 2026 | globenewswire.comSkye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination DevelopmentApril 2, 2026 | globenewswire.comSkye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...March 11, 2026 | finance.yahoo.comSkye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 11, 2026 | finanznachrichten.deSkye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategyMarch 11, 2026 | msn.comSkye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call TranscriptMarch 10, 2026 | seekingalpha.comSkye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 10, 2026 | globenewswire.comSkye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026March 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNSP, PTPI, LGVN, and SKYE Company DescriptionsCNS Pharmaceuticals NASDAQ:CNSP$4.17 -0.12 (-2.80%) Closing price 04:00 PM EasternExtended Trading$4.00 -0.17 (-4.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Longeveron NASDAQ:LGVN$0.74 -0.06 (-7.50%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.02 (+2.84%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Petros Pharmaceuticals NASDAQ:PTPI$0.0060 +0.00 (+3.45%) As of 11:37 AM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Skye Bioscience NASDAQ:SKYE$0.68 -0.02 (-3.00%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.15%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
